Updates in chimeric antigen receptor T-cell therapy for lymphoma
10.3760/cma.j.issn.1009-9921.2017.01.002
- VernacularTitle:嵌合抗原受体T细胞治疗淋巴瘤研究进展
- Author:
Zhitao YING
;
Jun ZHU
- Keywords:
Chimeric antigen receptor T-cell;
Lymphoma,B-cell;
Relapsed;
Refractory;
American society of Hematology Annual Meeting
- From:
Journal of Leukemia & Lymphoma
2017;26(1):3-4
- CountryChina
- Language:Chinese
-
Abstract:
Tremendous success has emerged in chimeric antigen receptor (CAR)-T cell therapy over the past few years, especially in leukemia and lymphoma. The first CAR-T cell product might be available in America in 2017 due to the emergence of the critical results. This paper focused on the key data presented at the 58th American Society of Hematology Annual Meeting.
